» Articles » PMID: 33718350

Differential CircRNA Expression Signatures May Serve As Potential Novel Biomarkers in Prostate Cancer

Overview
Specialty Cell Biology
Date 2021 Mar 15
PMID 33718350
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Circular RNAs (circRNAs), a recently discovered non-coding RNA, have a number of functions including the regulation of miRNA expression. They have been detected in a number of malignancies including prostate cancer (PCa). The differential expression pattern of circRNAs associated with PCa and androgen receptor (AR) status was investigated in this study. circRNA profiling was performed using a high throughout microarray assay on a panel of prostate cell lines, which consisted of normal, benign, and malignant cells ( = 9). circRNAs were more commonly significantly up-regulated ( < 0.05) than downregulated in malignant cell lines ( = 3,409) vs. benign cell lines ( = 2,949). In a grouped analysis based on AR status, there were 2,127 down-regulated circRNAs in androgen independent cell lines compared to 2,236 in androgen dependent cell lines, thus identifying a potential circRNA signature reflective of androgen dependency. Through a bioinformatics approach, the parental genes associated with the top 10 differentially expressed circRNAs were identified such as hsa_circ_0064644, whose predicted parental gene target is , and hsa_circ_0060539, whose predicted gene target is . Furthermore, we identified three circRNAs associated with the parental gene (hsa_circ_0021652, hsa_circ_0000288, and hsa_circ_0021647). Other studies have shown the importance of in PCa cell survival and drug resistance. Given the modified circRNA expression signatures identified here, these hypothesis generating results suggest that circRNAs may serve as potential putative diagnostic and predictive markers in PCa. However, further validation studies are required to assess the true potential of these markers in the clinical setting.

Citing Articles

Multiple roles of circular RNAs in prostate cancer: from the biological basis to potential clinical applications.

Zheng X, Song L, Cao C, Sun S Eur J Med Res. 2025; 30(1):140.

PMID: 40016786 PMC: 11866600. DOI: 10.1186/s40001-025-02382-0.


Circular RNA hsa_circ_0000288 protects against epilepsy in mice by binding to and stabilizing caprin1 protein.

Guo L, Lv N, Ji J, Gao C, Liu S, Liu Z Acta Pharmacol Sin. 2025; .

PMID: 39962265 DOI: 10.1038/s41401-025-01486-x.


Role of non-coding RNA in lineage plasticity of prostate cancer.

Tan W, Xiao C, Ma M, Cao Y, Huang Z, Wang X Cancer Gene Ther. 2024; 32(1):1-10.

PMID: 39496938 DOI: 10.1038/s41417-024-00834-z.


To investigate the role and potential mechanism of has_circ_RBMS3 in bone metastasis of breast cancer based on bioinformatics.

Long T, Tan M Cell Biochem Biophys. 2024; 82(3):2227-2236.

PMID: 38822975 DOI: 10.1007/s12013-024-01332-7.


Exploring the impact of circRNAs on cancer glycolysis: Insights into tumor progression and therapeutic strategies.

Hsu C, Faisal A, Jumaa S, Gilmanova N, Ubaid M, Athab A Noncoding RNA Res. 2024; 9(3):970-994.

PMID: 38770106 PMC: 11103225. DOI: 10.1016/j.ncrna.2024.05.001.


References
1.
Ramnarine V, Kobelev M, Gibb E, Nouri M, Lin D, Wang Y . The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Eur Urol. 2019; 76(5):546-559. DOI: 10.1016/j.eururo.2019.07.040. View

2.
Glazar P, Papavasileiou P, Rajewsky N . circBase: a database for circular RNAs. RNA. 2014; 20(11):1666-70. PMC: 4201819. DOI: 10.1261/rna.043687.113. View

3.
Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O . Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis. Mol Cell. 2017; 66(1):22-37.e9. PMC: 5387670. DOI: 10.1016/j.molcel.2017.02.017. View

4.
Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

5.
Dong Y, He D, Peng Z, Peng W, Shi W, Wang J . Circular RNAs in cancer: an emerging key player. J Hematol Oncol. 2017; 10(1):2. PMC: 5210264. DOI: 10.1186/s13045-016-0370-2. View